IL312997A - Human metapneumovirus vaccines - Google Patents
Human metapneumovirus vaccinesInfo
- Publication number
- IL312997A IL312997A IL312997A IL31299724A IL312997A IL 312997 A IL312997 A IL 312997A IL 312997 A IL312997 A IL 312997A IL 31299724 A IL31299724 A IL 31299724A IL 312997 A IL312997 A IL 312997A
- Authority
- IL
- Israel
- Prior art keywords
- skin
- energy
- ultrasound
- collagen
- tightening
- Prior art date
Links
- 241000342334 Human metapneumovirus Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 238000002604 ultrasonography Methods 0.000 claims description 204
- 238000000034 method Methods 0.000 claims description 162
- 239000013598 vector Substances 0.000 claims description 139
- 108010035532 Collagen Proteins 0.000 claims description 134
- 102000008186 Collagen Human genes 0.000 claims description 134
- 229920001436 collagen Polymers 0.000 claims description 134
- 238000011282 treatment Methods 0.000 claims description 117
- 210000001519 tissue Anatomy 0.000 claims description 94
- 230000036558 skin tension Effects 0.000 claims description 87
- 230000003902 lesion Effects 0.000 claims description 76
- 230000003685 thermal hair damage Effects 0.000 claims description 56
- 239000000835 fiber Substances 0.000 claims description 33
- 230000008602 contraction Effects 0.000 claims description 26
- 230000037303 wrinkles Effects 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 17
- 238000004925 denaturation Methods 0.000 claims description 11
- 230000036425 denaturation Effects 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 9
- 230000009286 beneficial effect Effects 0.000 claims description 8
- 238000005520 cutting process Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 4
- 210000000944 nerve tissue Anatomy 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 285
- 230000000694 effects Effects 0.000 description 32
- 230000008569 process Effects 0.000 description 19
- 238000004088 simulation Methods 0.000 description 13
- 210000004207 dermis Anatomy 0.000 description 9
- 238000004590 computer program Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000005070 sphincter Anatomy 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000617 arm Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002435 rhinoplasty Methods 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284405P | 2021-11-30 | 2021-11-30 | |
| PCT/US2022/080555 WO2023102373A1 (en) | 2021-11-30 | 2022-11-29 | Human metapneumovirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312997A true IL312997A (en) | 2024-07-01 |
Family
ID=84602059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312997A IL312997A (en) | 2021-11-30 | 2022-11-29 | Human metapneumovirus vaccines |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230310571A1 (https=) |
| EP (1) | EP4440608A1 (https=) |
| JP (1) | JP2024542635A (https=) |
| KR (1) | KR20240118798A (https=) |
| CN (1) | CN118338911A (https=) |
| AR (1) | AR127808A1 (https=) |
| AU (1) | AU2022399571A1 (https=) |
| CA (1) | CA3239417A1 (https=) |
| CO (1) | CO2024007274A2 (https=) |
| IL (1) | IL312997A (https=) |
| MX (1) | MX2024006240A (https=) |
| TW (1) | TW202340227A (https=) |
| WO (1) | WO2023102373A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| JP2026504862A (ja) | 2023-01-18 | 2026-02-10 | ファイザー・インク | 呼吸器疾患に対するワクチン |
| WO2025119162A1 (zh) * | 2023-12-04 | 2025-06-12 | 深圳深信生物科技有限公司 | 偏肺病毒(mpv)疫苗 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025210592A1 (en) | 2024-04-05 | 2025-10-09 | Sanofi Pasteur Inc. | Muscle cell lnp-mrna quality control assays |
| WO2025250938A2 (en) * | 2024-05-31 | 2025-12-04 | Modernatx, Inc. | Respiratory syncytial virus and metapneumovirus vaccines |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026027730A1 (en) * | 2024-07-31 | 2026-02-05 | Sanofi | Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof |
| CN121221752A (zh) * | 2025-02-14 | 2025-12-30 | 北京悦康科创医药科技股份有限公司 | 一种膜融合抑制多肽在抗副黏病毒科病毒感染中的应用 |
| CN119978144B (zh) * | 2025-02-14 | 2025-10-17 | 嘉译生物医药(杭州)有限公司 | 一种hMPV病毒融合蛋白F变体、mRNA疫苗及其应用 |
| CN119971017B (zh) * | 2025-04-16 | 2025-08-05 | 北京华诺泰生物医药科技有限公司 | 一种hmpv疫苗组合物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5684042A (en) | 1997-01-10 | 1997-11-04 | Medlogic Global Corporation | Cyanoacrylate compositions comprising an antimicrobial agent |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| AU2010264686A1 (en) * | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| EP2519636B8 (en) | 2009-12-28 | 2017-08-09 | DSM IP Assets B.V. | Production of hemagglutinin-neuraminidase protein in microalgae |
| IN2012DN06277A (https=) | 2009-12-28 | 2015-09-25 | Dsm Ip Assets Bv | |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| KR102451116B1 (ko) | 2011-10-27 | 2022-10-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| CN105051213A (zh) | 2013-03-14 | 2015-11-11 | 夏尔人类遗传性治疗公司 | 信使rna加帽效率的定量评估 |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| ES2949540T3 (es) | 2015-06-19 | 2023-09-29 | Massachusetts Inst Technology | 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula |
| WO2018089801A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| MX2019005470A (es) | 2016-11-10 | 2019-11-21 | Translate Bio Inc | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. |
| EP3558356A2 (en) * | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| EP4003311A1 (en) | 2019-07-23 | 2022-06-01 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
-
2022
- 2022-11-29 AU AU2022399571A patent/AU2022399571A1/en active Pending
- 2022-11-29 MX MX2024006240A patent/MX2024006240A/es unknown
- 2022-11-29 KR KR1020247021492A patent/KR20240118798A/ko active Pending
- 2022-11-29 CA CA3239417A patent/CA3239417A1/en active Pending
- 2022-11-29 IL IL312997A patent/IL312997A/en unknown
- 2022-11-29 WO PCT/US2022/080555 patent/WO2023102373A1/en not_active Ceased
- 2022-11-29 JP JP2024532179A patent/JP2024542635A/ja active Pending
- 2022-11-29 CN CN202280078895.3A patent/CN118338911A/zh active Pending
- 2022-11-29 AR ARP220103276A patent/AR127808A1/es unknown
- 2022-11-29 US US18/070,921 patent/US20230310571A1/en active Pending
- 2022-11-29 EP EP22830106.5A patent/EP4440608A1/en active Pending
- 2022-11-30 TW TW111145906A patent/TW202340227A/zh unknown
-
2024
- 2024-06-11 CO CONC2024/0007274A patent/CO2024007274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022399571A1 (en) | 2024-07-11 |
| TW202340227A (zh) | 2023-10-16 |
| CO2024007274A2 (es) | 2024-07-18 |
| KR20240118798A (ko) | 2024-08-05 |
| US20230310571A1 (en) | 2023-10-05 |
| AR127808A1 (es) | 2024-02-28 |
| CN118338911A (zh) | 2024-07-12 |
| CA3239417A1 (en) | 2023-06-08 |
| WO2023102373A1 (en) | 2023-06-08 |
| MX2024006240A (es) | 2024-06-11 |
| EP4440608A1 (en) | 2024-10-09 |
| JP2024542635A (ja) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312997A (en) | Human metapneumovirus vaccines | |
| US20250001216A1 (en) | Vector tightening | |
| US11666754B2 (en) | Apparatus and method of non-invasive directional tissue treatment | |
| KR101188931B1 (ko) | 지방 조직을 파괴하기 위한 장치 및 방법 | |
| US7494488B2 (en) | Facial tissue strengthening and tightening device and methods | |
| US20160220849A1 (en) | Method for treatment of tissue | |
| US20040206365A1 (en) | Method for treatment of tissue | |
| US20030236487A1 (en) | Method for treatment of tissue with feedback | |
| US20040093042A1 (en) | Method and apparatus for photothermal treatment of tissue at depth | |
| EP3294405B1 (en) | Apparatus of non-invasive directional tissue treatment using radiofrequency energy | |
| KR20220002932A (ko) | 피부 치료용 초음파 트랜스듀서 및 시스템 | |
| IL295965B1 (en) | Cosmetic device and method for cosmetic treatment of human mucosal tissue | |
| CN110213999B (zh) | 用于冷等离子体皮肤表面重修的装置和方法 | |
| Lee et al. | Updates on radiofrequency devices for skin tightening and body contouring | |
| Lee et al. | Surgical revision | |
| US12233288B1 (en) | Motion based methods for cosmetic ultrasound treatments | |
| US20260000918A1 (en) | Motion based methods for cosmetic ultrasound treatments | |
| RU2153668C1 (ru) | Биоэнергетический способ повышения тонуса организма | |
| KR102375905B1 (ko) | 고주파 치료용 핸드피스의 고주파 인가 방법 | |
| US20250259306A1 (en) | A system of identifying plurality of parameters of a subject's skin and a method thereof | |
| Jung et al. | High-Intensity Focused Ultrasound: A Satisfactory, Non-invasive Procedure for Crow� s Feet Wrinkles | |
| HK40067315A (zh) | 用於数个皮肤处理的超声波换能器及系统 | |
| Bogle et al. | Nonsurgical skin tightening | |
| WO2026011036A1 (en) | Haptic laser surgical tool | |
| Desai | Nonsurgical Lifting and Tightening |